1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Challenges

6. Antiviral Therapeutics Market, by Drug
6.1. Introduction
6.2. Hepatitis Antiviral Drug
6.3. Herpes Antiviral Drug
6.4. HIV Antiviral Drug
6.5. Influenza Antiviral Drug

7. Antiviral Therapeutics Market, by Therapy
7.1. Introduction
7.2. DNA Polymerase Inhibitors
7.2.1. Non-nucleosides
7.2.2. Purine Nucleoside Analogues
7.2.3. Pyrimidine Nucleoside Analogues
7.3. Neuraminidase Inhibitors
7.4. Protease Inhibitors
7.5. Reverse Transcriptase Inhibitors
7.5.1. Nonnucleoside RTIs
7.5.2. Nucleoside RTIs
7.5.3. Nucleotide RTIs

8. Antiviral Therapeutics Market, by Distribution
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Independent Pharmacy & Drug Store
8.4. Online Pharmacy

9. California Antiviral Therapeutics Market

10. Florida Antiviral Therapeutics Market

11. Illinois Antiviral Therapeutics Market

12. New York Antiviral Therapeutics Market

13. Ohio Antiviral Therapeutics Market

14. Pennsylvania Antiviral Therapeutics Market

15. Texas Antiviral Therapeutics Market

16. Competitive Landscape
16.1. FPNV Positioning Matrix
16.1.1. Quadrants
16.1.2. Business Strategy
16.1.3. Product Satisfaction
16.2. Market Ranking Analysis
16.3. Market Share Analysis, By Key Player
16.4. Competitive Scenario
16.4.1. Merger & Acquisition
16.4.2. Agreement, Collaboration, & Partnership
16.4.3. New Product Launch & Enhancement
16.4.4. Investment & Funding
16.4.5. Award, Recognition, & Expansion

17. Company Usability Profiles
17.1. Abbott Laboratories
17.2. AbbVie Inc.
17.3. Atea Pharmaceuticals
17.4. Aurobindo Pharma Limited
17.5. Bristol-Myers Squibb Company
17.6. Cipla Inc.
17.7. COCRYSTAL PHARMA, INC.
17.8. Daiichi Sankyo Co. Ltd.
17.9. Eli Lilly & Co.
17.10. F. Hoffmann-La Roche AG
17.11. Gilead Sciences Inc.
17.12. GlaxoSmithKline PLC
17.13. Johnson & Johnson Services
17.14. Merck & Co.
17.15. Pfizer Inc.
17.16. Sanofi S.A.
17.17. Schering-Plough Corporation
17.18. Venatorx Pharmaceuticals, Inc.
17.19. Vienna BioCenter

18. Appendix
18.1. Discussion Guide
18.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, 2020 VS 2026 (USD BILLION)
FIGURE 2. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2026 (USD BILLION)
FIGURE 3. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: MARKET DYNAMICS
FIGURE 4. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2020 VS 2026 (%)
FIGURE 5. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2020 VS 2026 (USD BILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2026
FIGURE 7. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, 2018-2026 (USD BILLION)
FIGURE 8. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 9. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, 2018-2026 (USD BILLION)
FIGURE 10. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 11. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, 2018-2026 (USD BILLION)
FIGURE 12. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 13. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, 2018-2026 (USD BILLION)
FIGURE 14. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 15. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2020 VS 2026 (%)
FIGURE 16. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2020 VS 2026 (USD BILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2026
FIGURE 18. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 19. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 20. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, 2018-2026 (USD BILLION)
FIGURE 21. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 22. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, 2018-2026 (USD BILLION)
FIGURE 23. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 24. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, 2018-2026 (USD BILLION)
FIGURE 25. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 26. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 27. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 28. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 29. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 30. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2026 (USD BILLION)
FIGURE 31. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 32. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, 2018-2026 (USD BILLION)
FIGURE 33. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 34. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, 2018-2026 (USD BILLION)
FIGURE 35. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 36. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, 2018-2026 (USD BILLION)
FIGURE 37. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 38. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (%)
FIGURE 39. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2020 VS 2026 (USD BILLION)
FIGURE 40. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2026
FIGURE 41. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2026 (USD BILLION)
FIGURE 42. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 43. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, 2018-2026 (USD BILLION)
FIGURE 44. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 45. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, 2018-2026 (USD BILLION)
FIGURE 46. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2020 VS 2026 (USD BILLION)
FIGURE 47. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 48. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 49. COMPETITIVE SCENARIO ANALYSIS IN UNITED STATES ANTIVIRAL THERAPEUTICS MARKET, BY TYPE

List of Tables

TABLE 1. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2026 (USD BILLION)
TABLE 4. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2026 (USD BILLION)
TABLE 5. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY STATE, 2018-2026 (USD BILLION)
TABLE 6. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY STATE, 2018-2026 (USD BILLION)
TABLE 7. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY STATE, 2018-2026 (USD BILLION)
TABLE 8. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY STATE, 2018-2026 (USD BILLION)
TABLE 9. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2026 (USD BILLION)
TABLE 10. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, BY STATE, 2018-2026 (USD BILLION)
TABLE 11. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, BY STATE, 2018-2026 (USD BILLION)
TABLE 12. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, BY STATE, 2018-2026 (USD BILLION)
TABLE 13. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, BY STATE, 2018-2026 (USD BILLION)
TABLE 14. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY STATE, 2018-2026 (USD BILLION)
TABLE 15. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY STATE, 2018-2026 (USD BILLION)
TABLE 16. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, BY STATE, 2018-2026 (USD BILLION)
TABLE 17. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, BY STATE, 2018-2026 (USD BILLION)
TABLE 18. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, BY STATE, 2018-2026 (USD BILLION)
TABLE 19. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, BY STATE, 2018-2026 (USD BILLION)
TABLE 20. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2026 (USD BILLION)
TABLE 21. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY STATE, 2018-2026 (USD BILLION)
TABLE 22. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY STATE, 2018-2026 (USD BILLION)
TABLE 23. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY STATE, 2018-2026 (USD BILLION)
TABLE 24. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: SCORES
TABLE 25. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 26. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 27. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: RANKING
TABLE 28. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 29. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 30. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 31. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 32. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 33. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 34. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET: LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
AbbVie Inc.
Atea Pharmaceuticals
Aurobindo Pharma Limited
Bristol-Myers Squibb Company
Cipla Inc.
COCRYSTAL PHARMA, INC.
Daiichi Sankyo Co. Ltd.
Eli Lilly & Co.
F. Hoffmann-La Roche AG
Gilead Sciences Inc.
GlaxoSmithKline PLC
Johnson & Johnson Services
Merck & Co.
Pfizer Inc.
Sanofi S.A.
Schering-Plough Corporation
Venatorx Pharmaceuticals, Inc.
Vienna BioCenter